Abstracts tagged "Disease Activity"

Abstract Number: 5 • 2017 Pediatric Rheumatology Symposium
Effects of Puberty on Systemic Lupus Erythematosus: Results of a multi-center prospective longitudinal observational study in children entering puberty with SLE
Kathleen O'Neil¹, Hermine Brunner², Andrew Zeft³, Anne Stevens⁴, Suzanne Li⁵, Tracey Wright⁶, Emily von Scheven⁷, B. Anne Eberhard⁸, C. Egla Rabinovich⁹ and Deborah M. Levy¹⁰, ¹Pediatrics, Indiana University, Indianapolis, IN, ²Rheumatology, PRCSG, Cincinnati, OH, ³Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ⁴University of Washington, Department of Pediatrics, Seattle, WA, ⁵Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁶Pediatrics/Rheumatology, University of TX Southwestern, Dallas, TX, ⁷Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, ⁸Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁹Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ¹⁰Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Lupus often presents during puberty, and when it affects pre-pubertal children, disease activity is thought to increase at puberty. Sex hormones play some role…
Abstract Number: 86 • 2016 ACR/ARHP Annual Meeting
Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture
Huifeng Yun¹, Jennifer Beaumont², Shuo Yang³, James Willig⁴, W. Ben Nowell⁵, Seth D. Ginsberg⁶, Kelly V. Clayton⁷, Shantana Hazel^7,8, Carole Wiedmeyer⁵ and Jeffrey Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Med - Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, ⁵CreakyJoints/Global Health Living Foundation, Upper Nyack, NY, ⁶Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, ⁷Global Healthy Living Foundation, Upper Nyack, NY, ⁸Sister Girl Foundation, Inc., Upper Nyack, NY, ⁹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patient-reported outcomes (PROs) are key to enabling the comprehensive assessment of patient-centered benefits in comparative effectiveness research (CER). However, the relationships between different PROMIS…
Abstract Number: 519 • 2016 ACR/ARHP Annual Meeting
Greater Fatigue at Baseline and Female Gender Predict Worse Disability in Early RA Despite Treatment to Target: A Comparison of Two Observational Cohort Studies from the United Kingdom
Sarah Twigg¹, Elizabeth M.A. Hensor², Jane E. Freeston¹, Ai Lyn Tan¹, Alan Tennant³, Paul Emery⁴, Ann Morgan⁵ and YEAR consortium, IACON consortium , ¹NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³Swiss Paraplegic Research,, Nottwil, Switzerland, ⁴NIHR Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom
Background/Purpose: Although disability is part of the ‘core set’ of outcomes for RA research recommended by OMERACT (1), current therapeutic strategies focus on inflammation. The…
Abstract Number: 772 • 2016 ACR/ARHP Annual Meeting
Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Givenchy Maree Garcia, Annalyn Urbano and Evelyn Salido, Section of Rheumatology, University of the Philippines - Philippine General Hospital, Manila, Philippines
Background/Purpose: Statins have been shown to have anti-inflammatory and immunomodulatory effects. In vitro studies show that these drugs inhibit inflammatory cells, decrease the expression of…
Abstract Number: 1226 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Association Between C-Reactive Protein and Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: Analysis of Two Clinical Practice Data Sets
E Alemao¹, Z Guo¹, L Burns¹, M Frits², Jonathan Coblyn², Michael Weinblatt² and NA Shadick², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women’s Hospital, Boston, MA
Background/Purpose: The association between inflammatory markers such as CRP or ESR and joint damage has been widely established in RA. Autoantibodies such as RF and…
Abstract Number: 1514 • 2016 ACR/ARHP Annual Meeting
Symptoms of Depression and Anxiety Predict Worse Disease Activity and Functional Disability in a Cohort of Established Rheumatoid Arthritis Patients
Christine Iannaccone¹, Taysir G. Mahmoud², Jing Cui³, Michael Weinblatt¹ and NA Shadick⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology Immunology & Allergy, Brigham & Women's Hosp, Boston, MA
Background/Purpose: Depression and anxiety disorders are common in RA patients, with the most recent prevalence estimates indicating that 16.8% of RA patients have a diagnosis…
Abstract Number: 1741 • 2016 ACR/ARHP Annual Meeting
Patients with Active Psoriatic Arthritis Achieving Minimal Disease Activity with Secukinumab Treatment Demonstrate Sustained Improvement of Function and Quality of Life
Laura C. Coates¹, Philip J Mease², Laure Gossec³, Bruce Kirkham⁴, Lawrence Rasouliyan⁵, Shephard Mpofu⁶, Steffen Jugl⁶, Chetan Karyekar⁷ and Kunal Gandhi⁷, ¹University of Leeds, Leeds, United Kingdom, ²Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ³Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France, ⁴Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁵RTI Health Solutions, Barcelona, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–IL-17A monoclonal antibody, previously demonstrated higher minimal disease activity (MDA)1 response rates and sustained improvements in patient reported outcomes2 among…
Abstract Number: 2159 • 2016 ACR/ARHP Annual Meeting
Allopurinol Use Is Associated with Lower Risk of Peripheral Vascular Disease in the US Elderly
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Gout is associated with higher cardiovascular disease risk. Based on our previous work, there is evidence that allopurinol use reduces the risk of myocardial…
Abstract Number: 2578 • 2016 ACR/ARHP Annual Meeting
Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression
Ozge Kockara¹, Merve Sibel Gungoren², Erdem Karabulut³, Sebnem Ataman⁴ and Filiz Akbiyik², ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Medical Biochemistry, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Progressive bone destruction occurs in rheumatoid arthritis (RA) due to imbalance of osteoblast/osteoclast activity. Bone morphogenetic proteins (BMPs) regenerate bone damage by stimulating the…
Abstract Number: 2814 • 2016 ACR/ARHP Annual Meeting
Immunofluorescence Pattern and Titer of the Antinuclear Antibody Test Correlate with Disease Activity in Patients with Systemic Lupus Erythematosus
Mônica Simon Prado¹, Alessandra Dellavance², Sílvia H. Rodrigues³ and Luis Eduardo C. Andrade^4,5, ¹Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, São Paulo, Brazil, ²Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ³Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil, ⁴Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil, ⁵Fleury Health and Medicine, Sao Paulo, Brazil
Background/Purpose: Antinuclear antibody (ANA) indirect immunofluorescence (IIF) assay on HEp-2 cells (HEp-2-ANA) is an important element for diagnosis and classification of Systemic Lupus Erythematosus (SLE),…
Abstract Number: 3083 • 2016 ACR/ARHP Annual Meeting
Utility of Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Short Form for Understanding Interplay Between Patient-Reported Outcome Measures and Physician Driven Disease Activity Measures
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng², Jason Lyons², Anthony Fabio² and Larry W. Moreland¹, ¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology, University of Pittsburgh, School of Public Health, Pittsburgh, PA
Background/Purpose: Discordance between patient and physician assessment of rheumatoid arthritis (RA) disease activity strongly associates with pain scores. Patient-reported outcomes measurement information system (PROMIS) 29…
Abstract Number: 115 • 2016 ACR/ARHP Annual Meeting
Early Inflammatory Arthritis Presentation, Management and Outcomes in Canadian Aboriginal Patients
Sujay Nagaraj¹, Cheryl Barnabe², Orit Schieir³, Vivian P. Bykerk⁴, Janet Pope⁵, Shahin Jamal⁶, Gilles Boire⁷, Edward Keystone⁸, Diane Tin⁹, Boulos Haraoui¹⁰, J Carter Thorne¹¹, Carol Hitchon¹² and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁸Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Institute de Rheumatologie, Montreal, QC, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Differences in access to care that influence the timing and quality of treatment interventions may create outcome inequities for Aboriginal patients with inflammatory arthritis.…
Abstract Number: 522 • 2016 ACR/ARHP Annual Meeting
Patient-Provider Discordance in Global Assessments of Disease Activity in Patients with Rheumatoid Arthritis: Persistence, Predictors and Impact
Divya N.V Challa¹, Zoran Kvrgic¹, Cynthia S. Crowson², Daniel Schaffer¹, Thomas G. Mason II³, Scott T. Persellin⁴, Clement Michet Jr.¹, Theresa L. Wampler Muskardin¹, Kerry Wright¹, Eric L. Matteson¹ and John M. Davis III⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology - Department of Medicine, Mayo Clinic Rochester, Rochester, MN, ⁴Department of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Patient-provider discordance in global assessment (GA) of disease activity is a potential threat to patient-centered management of individuals with RA. The estimated prevalence of…
Abstract Number: 786 • 2016 ACR/ARHP Annual Meeting
Complement Split Product iC3b and C3 Blood Levels Best Associate with Active and Clinically Meaningful Changes in SLE Disease Activity
Alfred Kim¹, Deepali Sen², Vibeke Strand³, Qiang John Fu⁴, Nancy Mathis¹, Robin Bruchas⁵, Nick Staten⁵, Martin Schmidt⁶, Paul Olson⁵, Chad Stiening⁵ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³Stanford University School of Medicine, Palo Alto, CA, ⁴Biostatistics, Saint Louis University, Saint Louis, MO, ⁵Kypha, Inc., Saint Louis, MO, ⁶Kypha, Inc., St. Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 1331 • 2016 ACR/ARHP Annual Meeting
Disease Patterns and Long Term Outcome Amongst Patients with Relapsing Polychondritis – Single Centre Experience
Chee Ken Cheah, Shirish Sangle (Joint First Author) and David D'Cruz, Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: Relapsing polychondritis (RP) is a rare autoimmune disorder characterized by cartilage inflammation and damage. Chronic RP may lead to sequelae due to cartilage tissue…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].